HCC accounts for up to 90% primary liver malignancies [7]. Hepatocellular carcinoma is an extremely lethal disease as its mortality rate is almost 100 % i.e the incidence rate equals mortality rate [3]. Due to the poor survival rate of approximately 5%, only few patients tend to receive radical treatment [3]. More than 80% of the cases are reported from developing countries [6]. HCC is preceded by chronic liver inflammation which can occur possibly in the background of inly chronic viral infections, toxins, autoimmune disorders and metabolic syndromes [1]. In Eastern Asia the most common risk factors are hepatitis B and C infection and aflatoxin exposure [8].

The risk of HCC in patients with Hepatitis C infection increases up to 17 fold [9]. Annual incidence is 2-6% which may take up to two decades to develop [9]. Hepatocarcinogenesis is a multistep process and there is slow accumulation of genetic mutations [9]. According to Pakistani statistics, 58% of the reported cases of HCC are Hepatitis C positive and 25.3 % are positive for Hepatitis B [6]. In our study the frequency of HCV positive HCC was much higher i.e., 70.3% while only 3.4% patients were positive for Hepatitis B. Although the statistics may vary in different parts of the country as our study is mited to single institution and no national cancer registry statistics are available. There is no such parameter available through which we can do risk evaluation and casualty assessment in HCV positive HCC patients. There is marked demographic variation among different populations. HCC is common among male population, and among the most common malignancies among adult males in Pakistan. Overall incidence ratio among male to female is 3:1 with shifting trends towards younger population3. In our study 70.3 % patients were male and 29.7% were females making the incidence radio of 2.37:1 in our population. The majority of our patients presented in 5th and 6th decade of life. In our study one patient of 17 years of age was also enrolled who had presented with late stage HCC.

HCC remains latent for 3.2 years [6]. It is very difficult to differentiate the diffuse tumors from the cirrhotic liver tissue but the early diagnosis during the subclinical period has a propensity to cure the disease [6]. Screening is usually done through ultrasound along with measurement of serum levels of Alpha Fetoprotein (AFP) [6]. Asian Oncology Summit recommendations for screening are 6 monthly ultrasound plus measurement of serum AFP levels [10]. The sensitivity of ultrasound increases up to 79% when correlated with AFP levels [11]. As compared to the western world where thereare well established programs for screening of high risk patients of chronic liver disease, HCC is detected in earlier stages, whileonly up to 10 % patients in Pakistan undergo routine screening tests [6]. Unfortunately none of the patients enrolled in our study underwent HCC screening and were detected incidentally when became symptomatic for the disease. At presentation majority of the patients had raised AFP levels in our study group. Patients of HCC may remain asymptomatic for long periods of time or may present with chronic liver disease. Majority of the patients had not receivedany systemic treatment for HCV or had poor compliance. Clinical presentation may vary from patient to patient. In our study most common presenting symptoms were abdominal pain and jaundice.

Contrast enhanced Multiphasic MRI and CT scan of liver isconsidered to be the classic imaging modality to make the definitive diagnosis of HCC [6]. A meta-analysis showed that USG is although less sensitive but most specific up to 97%. Tumor marker AFP is advised along with imaging studies to reach to the final diagnosis. Elevated AFP levels of >400 ng/ml is associated with active HCC. Biopsy is only indicated in HCC when there are suspicious nodules or suspicion of ome other malignancy [6]. Biopsy is also indicated only when serum CA19-9 and CEA levels are raised and cholangiocarcinoma needs to be ruled out [13]. In our study the diagnosis was made through the combination of imaging via Triphasic CT scan and serum AFP levels in all the patients. Biopsy was not advised to any of our patients. Most of the patients in our setup presented in the advanced stages and markedly elevated AFP levels associated with HCV positivity.

To find out the extent of the disease many staging systems have been developed in clinical practice [14]. AJCC TNM staging system is employed in our setup to find out the extent of HCC. It includes the standard method of tumor, node and metastasis evaluation and is a redictor of prognosis and treatment outcome. In Pakistan up to 62% patients present with multifocal HCC and 44.3% patients present ith large tumor sizes of >5 cm [6]. In our study 58.6% patients presented with multifocal or large space occupying liver lesions stageIV disease, followed by 27.3% patients with stage III disease. 12.4% patients had stage II disease and only 1.2% had stage I HCC. HCV+ patients presented in more advanced stages as compared to HCVpatients and had Child-Pugh class B and C according to Child-Pugh classification system.

Ideally all cases of HCC should be discussed in multidisciplinary tumor board to reach upon a treatment plan. It is a dilemma that ‘Cure’ is usually not achieved in Hepatocellular carcinoma and there is no single treatment option which has been agreed upon in thistumor. Most of the patients in our study were subjected to palliative treatments after initial evaluation and discussion in tumor board. The treatment options are potentially curative, palliative and supportive and none of them is considered definite therapy [15]. The potentially curable treatment options include surgical resection, liver transplant and radiofrequency ablation which are usually offered to the early stage HCC patients [15]. Surgical resection is considered to be the mainstay of treatment in patients with good performance status and Child class A having very early stage solitary tumors with no cirrhosis and portal hypertension [15]. Only 5-10% patients are considered fit for surgery with five year overall survival and recurrence rate up to 70% and 68% respectively in HCC patients [15]. None of our study group patients was amenable for surgical resection. Referring to the Milan criteria solitary tumor of <5 cm or up to 3 tumors of <3 cm are considered for liver transplant [15]. Active Hepatitis C infection is likely to cause tumor recurrence in up to 40% of the liver transplant patients [16]. Other poor prognostic features likely to cause recurrence include multilobar disease, macroscopic vascular invasion, high grade tumor and pretreatment AFP levels of >300 ng/ml [17]. The lack of good quality donor organs and expertise, liver transplant is a very limited treatment approach while other alternative approaches are usually considered in this regard. None of the patients in our study was offered liver transplant.

Another well-defined treatment approach in HCC is Radiofrequency Ablation RFA. It is an ablative procedure and is indicated in small well defined tumors of < 5 cm and has best results when tumor size is < 2 cm 18. Five year overall survival rate is from 40 to 70% [18]. In our set up due to the limited resources andexpertise available few patients with early stage disease are offered RFA treatment. Unfortunately in our study even among the very few patients with early stage HCC, only few were able to undergo ablative procedure due to poor performance status, lack of facilities and financial burdens. Nonsurgical treatment options are rather palliative. These include Transarterial Chemoembolization (TACE), Targeted therapy and chemotherapy.

The patients with child class C and thrombosis of portal veincannot be offered TACE as it leads to hepatic failure and extrahepatic disease [19]. The two Pakistani studies have shown that TACE is the most commonly used treatment in HCC patients (60.7% and 38.2%) [6]. While these are the statistics from well-established tertiary caresetups with overall survival of 45% at 5 years and 10% at 1 year [6]. While according to our study the results are even worse, as majority of our patients fell under child class B and C and most of them had portal vein thrombosis at the time of presentation so TACE was offered to only few of them. A targeted agent sorafenib is a tyrosine kinase inhibitor which is administered in the advanced stage and inoperable HCC patients. A study published by Cheng el al. in Asian patients sorafenib is considered as a first line therapy in patients who present in late stages and are not likely to benefit from TACE and ablative therapies [20]. Sorafenib is also indicated in the patients with Hepatitis B and C and alcohol induced HCC. Sorafenib has minimal benefit in late stage patients with median overall survival of 2.8 months [19]. Patients with child class C having deranged clotting profile are not considered fit for targeted therapy due to increased risk of bleeding [20]. In our study patients were offered targeted therapy considering their stage of the disease, performance status, child class and affordability. Usually single agent chemotherapy drugs, doxorubicin and gemcitabine are employed in the treatment as compared to combination chemotherapy [19]. The therapeutic efficacy of both the drugs is similar [19]. In our study, single agent doxorubicin was offered in advanced stages only to the patients with good performance status and child class A. The external beam in the HCC has extremely limited role. The tolerance dose of liver is up to 30 Gy and normal hepatocytes are radiosensitive [21]. However in our study, the patients presented with spinal cord compression, bone and brain metastasis (total of 4.9% patients) were offered palliative hypofractionated external beam radiotherapy. The dosage protocols most frequently used in our setup are 30 Gy in 10 fractions, 20 Gy in 05 fractions and 08 Gy in single fraction.